参考文献

[1]WANG Y,ZHENG Y,ZHANG L,et al.Stability of nanosuspensions in drug delivery[J].J Control Release,2013,172(3):1126-1141.

[2]MULLER R H,GOHLA S,KECK C M.State of the art of nanocryst als special features,production,nanotoxicology aspects and intracellular delivery[J].Eur J Pharm Biopharm,2011,78(1):1-9.

[3]袁慧玲,易加明,张彩云,等.纳米混悬剂的制备方法及给药途径研究进展[J].中国新药杂志,2014,23(3):297-301.

[4]谢元彪,许俊男,陈颖翀,等.纳米晶体技术在难溶性药物中的应用进展与思考[J].世界科学技术-中医药现代化,2016,18(10):1788-1793.

[5]KALEPU S,NEKKANTI V.Improved delivery of poorly soluble compounds using nanoparticle technology:a review[J].Drug Deliv Transl Res,2016,6(3):1-14.

[6]陈亚军.齐墩果酸纳米悬浮液研究[D].武汉:华中科技大学,2005.

[7]GAO L,LIU G Y,WANG X Q,et al.Preparation of a chemically stable quercetin formulation using nanosuspension technology[J].Int J Pharm,2011,404(1-2):231-237.

[8]LEI Y,KONG Y,SUI H.Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation[J].Drug Deliv Transl Res,2016,6(5):519-525.

[9]HONG C,DANG Y,LIN G,et al.Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization:an in vitro and in vivo evaluation[J].Int J Pharm,2014,477(1-2):251-260.

[10]SHEN BAODE,WU NA,SHEN CHENGYING,et al.Hyperoside nanocrystals for HBV treatment:process optimization,in vitro and in vivo evaluation[J].Drug Dev Ind Pharm,2016,42(11):1772-1781.

[11]YUE P F,LI Y,WAN J,et al.Process optimization and evaluation of novel baicalin solid nanocrystals[J].Int J Nanomedicine,2013(8):2961-2973.

[12]何小龙,宋红萍.柚皮素纳米晶体的制备及体外性质研究[J].中国医院药学杂志,2016,36(4):289-293.

[13]GAO LEI,ZHANG DIANRUI,CHEN MINGHUI,et al.Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement[J].Drug Dev Ind Pharm,2007,33(12):1332-1339.

[14]沈成英,申宝德,徐平华,等.灵芝三萜纳米混悬凝胶剂的制备及其体外透皮研究[J].中草药,2014,45(19):2770-2775.

[15]张彩云,袁慧玲,易加明,等.姜黄素纳米混悬剂的制备及体外释放研究[J].中国药学杂志,2014,49(21):1917-1922.

[16]刘肖,刘娟,庞建云,等.微型化介质研磨法制备槲皮素纳米混悬剂[J].中国中药杂志,2017,42(15):2984-2988.

[17]王静娴,李文,陈婷,等.穿心莲内酯纳米混悬剂的制备及评价[J].南京中医药大学学报,2017,33(3):313-316.

[18]贺凌云.吴茱萸次碱纳米混悬剂的构建、表征及体内评价[D].长沙:中南大学,2010.

[19]郝吉福.白藜芦醇纳米混悬剂改善口服生物利用度及经鼻脑靶向递药系统研究[D].济南:山东大学,2015.

[20]ZHANG J,LV H,JIANG K,et al.Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal[J].Int J Pharm,2011,420(1):180-188.

[21]张文君,吴凡,王鑫,等.星点设计-效应面法优化藤黄酸纳米混悬剂处方[J].中国药剂学杂志,2014,12(2):43-52.

[22]吴浩天,赵京华,贾德超,等.莪术醇纳米混悬剂的制备和体外释药研究[J].沈阳药科大学学报,2017,34(8):623-628.

[23]谢燕瑾,俞婷婷,楼炜.人参皂苷Rg3纳米晶体的制备及抗肿瘤作用[J].医药导报,2016,35(11):1186-1189.

[24]沈刚,李娟娟,程玲,等.制备波棱瓜子总木脂素纳米混悬剂[J].中成药,2015,37(10):2153-2158.

[25]程玲,郑娟,沈刚,等.p H依赖型黄芩苷纳米晶体结肠靶向微丸的制备及体外释药研究[J].中成药,2016,38(2):298-303.

[26]靳世英,袁海龙,靳士晓,等.黄芩苷纳米晶体微丸的制备及其药代动力学初步研究[J].中国中药杂志,2013,38(8):1156-1159.

[27]LEI Y,KONG Y,SUI H.Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation[J].Drug Deliv Transl Res,2016,6(5):519-525.

[28]张明珠,李怡静,苏文晶,等.雷公藤红素纳米混悬剂的制备及其抗肿瘤作用研究[J].现代药物与临床,2016,31(10):1528-1534.

[29]SHI Y J,JIN H,SHI X J.Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method[J].Chin J Nat Med,2014,12(1):71-80.

[30]MALAMATARI M,SOMAVARAPU S,TAYLOR K M,et al.Solidification of nanosuspensions for the production of solid oral dosage forms and inhalabledry powders[J].Expert Opin Drug Deliv,2016,13(3):435-450.

[31]KOCBEK P,BAUMGARTNER S,KRISTL J.Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs[J].Int J Pharm,2006,312(1-2):179-186.

[32]WANG L,DU J,ZHOU Y,et al.Safety of nanosuspensions in drug delivery[J].Nanomedicine,2017,13(2):455-469.

[33]KECK C M,MULLER R H.Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization[J].Eur J Pharm Biopharm,2006,62(1):3-16.

[34]MULLER R H,RUNGE S,RAVELLI V,et al.Oral bioavailability of cyclosporine:solid lipid nanoparticles(SLN)versus drug nanocrystals[J].Int J Pharm,2006,317(1):82-89.

[35]周小圆,林华庆,雷伟.难溶性药物纳米晶体的研究进展[J].中南药学,2013,11(5):353-358.

[36]郑爱萍,石靖.纳米晶体药物研究进展[J].国际药学研究杂志,2012,39(3):177-183.

[37]钦富华,俞佳丹,计竹娃,等.熊果酸纳米混悬凝胶剂的制备及其体外透皮研究[J].广东药科大学学报,2017,33(3):285-289.

[38]张小飞,果秋婷.姜黄素纳米混悬剂的制备及大鼠体内药动学研究[J].中药材,2015,38(1):163-166.

[39]刘营营,肖瑶,苏文晶,等.高载药量甘草次酸纳米混悬剂的制备及其大鼠体内药动学研究[J].药物评价研究,2016,39(1):74-79.

[40]GAO LEI,ZHANG DIAANRUI,CHEN MINGHUI,et al.Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions[J].Int J Pharm,2008,355(1-2):321-327.

[41]沈刚,沈成英,程玲,等.波棱瓜子总木脂素纳米混悬剂胶囊的保肝作用评价[J].中国药学杂志,2015,50(12):1038-1042.

[42]夏智,黄厚才,宋捷,等.姜黄素纳米混悬剂对亚急性衰老模型小鼠抗衰老指标的影响[J].中兽医医药杂志,2017,36(1):45-48.

[43]LOU HAIYAN,ZHANG XIUMEI,GAO LEI,et al.In vitro and in vivo antitumor activity of oridonin nanosuspension[J].Int J Pharm,2009,379(1):181-186.

[44]LOU HAIYAN,GAO LEI,WEI XINBING,et al.Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22tumor bearing mice[J].Colloids Surf B Biointerfaces,2011,87:319-325.